Section Arrow
Quote
VRAX.NASDAQ
- Virax Biolabs Group Limited
(Financial Status)
Quotes are at least 15-min delayed:2025/08/19 04:35 EDT
Pre Market
Last
 0.7832
0 (0.00%)
Bid
0.72
Ask
0.7832
High 0.7832 
Low 0.7829 
Volume 23 
Regular Hours
Last
 0.7832
+0.0084 (+1.08%)
Day High 
0.79 
Prev. Close
0.7748 
1-M High
1.14 
Volume 
13.11K 
Bid
0.72
Ask
0.7832
Day Low
0.741 
Open
0.75 
1-M Low
0.7222 
Market Cap 
3.36M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.78 
20-SMA 0.87 
50-SMA 0.87 
52-W High 8.9999 
52-W Low 0.7222 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.62/-1.01
Enterprise Value
3.66M
Balance Sheet
Book Value Per Share
1.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
6.33K
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.07+0.0105+17.65%-- 
Pre Market 0.0664 -0.0036 -5.14%
ASBPAspire Biopharma Holdings Inc.0.59+0.231+64.35%-- 
Pre Market 0.5371 -0.0529 -8.97%
SNGXSoligenix Inc.4.96+2.18+78.42%-- 
Pre Market 4.03 -0.93 -18.75%
PPCBPropanc Biopharma Inc5.85+2.98+103.83%-- 
Pre Market 4.81 -1.04 -17.78%
BTAIBioXcel Therapeutics Inc5.67+0.19+3.47%-- 
Pre Market 4.92 -0.75 -13.23%
Quotes are at least 15-min delayed：2025/08/19 04:35 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developinga proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.